These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27481010)

  • 21. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
    Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
    Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.
    Parisi C; Mastoraki S; Markou A; Strati A; Chimonidou M; Georgoulias V; Lianidou ES
    Clin Chim Acta; 2016 Oct; 461():156-64. PubMed ID: 27510924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
    Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
    Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-free circulating tumor DNA in cancer.
    Qin Z; Ljubimov VA; Zhou C; Tong Y; Liang J
    Chin J Cancer; 2016 Apr; 35():36. PubMed ID: 27056366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
    Hahn AW; Gill DM; Maughan B; Agarwal A; Arjyal L; Gupta S; Streeter J; Bailey E; Pal SK; Agarwal N
    Oncotarget; 2017 May; 8(20):33614-33620. PubMed ID: 28431395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
    Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
    Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.
    He J; Tan W; Ma J
    Future Oncol; 2017 Apr; 13(9):787-797. PubMed ID: 28073294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies.
    Heitzer E; Ulz P; Geigl JB; Speicher MR
    Mol Oncol; 2016 Mar; 10(3):494-502. PubMed ID: 26778171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.
    Bratman SV; Newman AM; Alizadeh AA; Diehn M
    Expert Rev Mol Diagn; 2015 Jun; 15(6):715-9. PubMed ID: 25773944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
    Tsao SC; Weiss J; Hudson C; Christophi C; Cebon J; Behren A; Dobrovic A
    Sci Rep; 2015 Jun; 5():11198. PubMed ID: 26095797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time.
    Hahn AW; Stenehjem D; Nussenzveig R; Carroll E; Bailey E; Batten J; Maughan BL; Agarwal N
    Cancer Treat Res Commun; 2019; 19():100120. PubMed ID: 30743187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating Biomarkers for Prediction of Treatment Response.
    Cappelletti V; Appierto V; Tiberio P; Fina E; Callari M; Daidone MG
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):60-3. PubMed ID: 26063889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient monitoring through liquid biopsies using circulating tumor DNA.
    Ulz P; Heitzer E; Geigl JB; Speicher MR
    Int J Cancer; 2017 Sep; 141(5):887-896. PubMed ID: 28470712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.
    Lebofsky R; Decraene C; Bernard V; Kamal M; Blin A; Leroy Q; Rio Frio T; Pierron G; Callens C; Bieche I; Saliou A; Madic J; Rouleau E; Bidard FC; Lantz O; Stern MH; Le Tourneau C; Pierga JY
    Mol Oncol; 2015 Apr; 9(4):783-90. PubMed ID: 25579085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients.
    Taback B; Fujiwara Y; Wang HJ; Foshag LJ; Morton DL; Hoon DS
    Cancer Res; 2001 Aug; 61(15):5723-6. PubMed ID: 11479206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New blood markers detection technology: A leap in the diagnosis of gastric cancer.
    Beeharry MK; Liu WT; Yan M; Zhu ZG
    World J Gastroenterol; 2016 Jan; 22(3):1202-12. PubMed ID: 26811658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liquid Biopsies in Oncology and the Current Regulatory Landscape.
    Strotman LN; Millner LM; Valdes R; Linder MW
    Mol Diagn Ther; 2016 Oct; 20(5):429-36. PubMed ID: 27324559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatic cancer: Are "liquid biopsies" ready for prime-time?
    Lewis AR; Valle JW; McNamara MG
    World J Gastroenterol; 2016 Aug; 22(32):7175-85. PubMed ID: 27621566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.